Norvatis’ Xolair Aids In The Treatment of Asthma Among Children
“A new study suggests that Novartis drug Xolair may aid in the treatment of asthma, the leading cause of chronic illness in children, especially for those living in highly polluted inner-city areas. Asthma affects as many as 10% to 12% of children in the United States and for unknown reasons is steadily increasing.” http://www.medicalnewstoday.com/articles/219456.php
Respiratory ailments can start at any age but some children have their symptoms at the age 5. Among inner-city children with asthma, they are susceptible to air pollution at below level of quality air standards. The new research suggests that together with the drug omalizumab (Xolair) in asthma therapy decreases the seasonal attacks and also the need for controller medication for those inner-city children in particular, regardless of the severity of asthma.
According to Suzanne Steinbach, MD, an associate professor of paediatrics at Boston University School of Medicine, said that they found that the omalizumab (Xolair, Novartis), as equally as effective at all levels of the severity of asthma and all ages.
Together with her colleagues, they enrolled 419 inner-city patients at the age 6 to 20 years old and they have found out that omalizumab decrease the symptoms of asthma by 25% and the asthma exacerbation by 30% compared with the placebo.
Furthermore, children who are in omalizumab group have fewer exacerbations between the months of September and November which is the peak season of asthma. On the other side, 100% in the placebo group have increased exacerbation for summer to fall and the inhaled-corticosteroid use rise up. On the treatment group, the rates stayed static.
In today’s time, the incidence of asthma in children is increasing worldwide. The trend has been link to the environmental factors like, air pollution. It is advised that it is important to have an understanding that the indoor triggers can play as much as of the role of the outdoor triggers in bringing the asthma attack.
Researchers then concluded that, because omalizumab targets a specific immunologic pathway of the main importance in asthma, individuals who suffer from asthma and the allergic sensitizations are the ones candidate for the treatment. More observations will help in the selection of the patients for omalizumab. It will take considerations on the aspects of disease management.
